From the Guidelines
There is no established relationship between Urinary Tract Infection (UTI) and Zytiga (Abiraterone).
Overview of Zytiga (Abiraterone)
- Zytiga (Abiraterone) is used in the treatment of metastatic non-castrate prostate cancer, often in combination with Androgen Deprivation Therapy (ADT) 1.
- The recommended dose of abiraterone is 1,000 mg with either prednisolone or prednisone 5 mg once daily until treatment for metastatic castration-resistant prostate cancer (mCRPC) is initiated 1.
Relationship with UTI
- None of the provided evidence suggests a relationship between Urinary Tract Infections (UTIs) and the use of Zytiga (Abiraterone) in the treatment of prostate cancer.
- The evidence focuses on the efficacy and safety of abiraterone in combination with ADT for metastatic non-castrate prostate cancer, without mention of UTIs as a side effect or complication 1.
Monitoring and Side Effects
- Monitoring for blood pressure, renal, and hepatic function is recommended due to potential side effects such as severe hypertension, cardiac disorders, and liver toxicity 1.
- However, UTI is not listed among the potential side effects or complications of abiraterone treatment in the provided evidence.
From the Research
Relationship between Urinary Tract Infection (UTI) and Zytiga (Abiraterone)
- The relationship between UTI and Zytiga (Abiraterone) is observed in several studies, which suggest that Abiraterone may be associated with an increased risk of UTIs 2, 3.
- A study published in 2013 found that UTI was one of the most common side effects of Abiraterone, affecting more than 10% of patients 2.
- Another study published in 2024 compared the risk of infection between Abiraterone and Enzalutamide, and found that Abiraterone was associated with a higher risk of UTIs, although the difference was not statistically significant 4.
- A real-world analysis of hospitalizations among veterans treated with Abiraterone or Enzalutamide found that Abiraterone was associated with a greater increase in rates of UTIs, as well as other infections such as sepsis and pneumonia 3.
- While these studies suggest a potential link between Abiraterone and UTIs, it is essential to note that UTIs can also be caused by other factors, such as bacterial infections, and that the relationship between Abiraterone and UTIs may be complex and influenced by various factors 5, 6.
Key Findings
- Abiraterone is associated with an increased risk of UTIs in some studies 2, 3.
- The difference in UTI risk between Abiraterone and Enzalutamide was not statistically significant in one study 4.
- Abiraterone is associated with a higher risk of other infections, such as sepsis and pneumonia 3.
- UTIs can be caused by various factors, including bacterial infections, and the relationship between Abiraterone and UTIs may be complex 5, 6.